content: <HTML><HEAD>
  <TITLE>Prepared by R.R. Donnelley Financial -- Form 8-K Dated July 22, 2002</TITLE>
  </HEAD>
    <BODY BGCOLOR="WHITE">
  
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="5" COLOR="#000000"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></DIV> <DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="3" COLOR="#000000"><B>WASHINGTON, D.C. 20549 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR NOSHADE WIDTH="19%" COLOR="#000000"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="5" COLOR="#000000"><B>FORM 8-K </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="3" COLOR="#000000"><B>CURRENT REPORT
  </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="3" COLOR="#000000"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="3" COLOR="#000000"><B>SECURITIES EXCHANGE
  ACT OF 1934 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Date of Report (Date of earliest event reported): July 22,
  2002 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="5" COLOR="#000000"><B>CONCEPTUS, INC. </B></FONT></DIV> <DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Exact name of registrant as specified in charter) </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center">
  <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">
  
  <TR>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Delaware</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(State or other
  jurisdiction of</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>incorporation or organization)</B></FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>000-27596</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Commission file
  number)</B></FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>94-3170244</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(I.R.S.
  employer</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>identification no.)</B></FONT></DIV> </TD> </TR>
   </TABLE> </DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>1021 Howard Avenue </B></FONT></DIV> <DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>San Carlos, CA 94070 </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Address of principal executive offices) (Zip code) </B></FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Registrant&#146;s telephone number, including area code: (650) 802-7240 </B></FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <HR NOSHADE WIDTH="19%" COLOR="#000000">
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#CCEEFF" WIDTH="100%" ALIGN="CENTER">
  
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>ITEM 5.&nbsp;&nbsp;&nbsp;&nbsp;OTHER EVENTS. </B></FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">On July 22, 2002, Conceptus, Inc. issued a press release announcing that the Obstetrics and Gynecological Devices Advisory Committee of the United States Food
  and Drug Administration (FDA) recommended approval for Essure</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>&#153;</SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><SUP></SUP>. Text of the press release follows:
  </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Rockville, MD, July 22, 2002 &#150; Conceptus, Inc. (NASDAQ NM: CPTS) today announced that the Obstetrics and Gynecological Devices
  Advisory Committee of the United States Food and Drug Administration (FDA) recommended approval for Essure</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>&#153;</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"
  COLOR="#000000"><SUP></SUP>, the first alternative to tubal ligation for women seeking permanent contraception. The committee, by a vote of 8-0 with one abstention, recommended that Essure be approved once certain conditions are met. These
  conditions include changes to the labeling and implementation of the company&#146;s pre-existing plan to conduct post-marketing surveillance. Although Advisory Committee recommendations are not binding on the FDA, typically FDA final determinations
  are consistent with their recommendations. In May, the Essure PMA (Pre-Market Approval Application) was granted expedited review status by the FDA. The Essure device is investigational in the United States and currently marketed in Australia,
  Europe, Singapore and Canada. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Currently, an estimated 700,000 American women undergo tubal ligation each year, making it the most common
  form of contraception in the United States. Unlike tubal ligation, which requires cutting into the abdominal cavity, and is typically done under general anesthesia with a four to six day recovery period, Essure requires no incisions, can be
  performed without general anesthesia and most patients are able to return to their regular physical activities within one day. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2"
  COLOR="#000000">&#147;After researchers have worked for more than three decades to develop an alternative to surgical tubal ligation, Conceptus is extremely proud to have developed Essure and be one step closer to bringing this breakthrough option
  to women seeking permanent birth control,&#148; said Steve Bacich, President and CEO of Conceptus. &#147;We are pleased that the Advisory Committee has recommended Essure for approval. When all FDA questions are answered, and if approval is given,
  we will work to make the procedure available as quickly as possible to women in the United States.&#148; </FONT></DIV> <P></P>
   <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">2 </FONT></DIV>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#CCEEFF" WIDTH="100%" ALIGN="CENTER">
  
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">&#147;Alternatives to incisional permanent birth control procedures represent an unmet need in this
  country,&#148; said Jay M. Cooper, M.D., founder and medical director of Women&#146;s Health Research Center, Phoenix, Arizona, and the principal U.S. investigator of Essure. &#147;By offering women a procedure without an incision, without general
  anesthesia and without significant disruption to their family or work life, Essure could ultimately change the face of permanent contraception.&#148; </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV>
  <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>About Essure </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Essure deploys a
  soft micro-insert into the fallopian tube through the cervix using a minimally invasive transcervical tubal access catheter. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or
  blockage in the fallopian tube. An Essure procedure does not require cutting or penetrating the abdomen and can be performed in a less costly procedure setting without general anesthesia. Accordingly, a woman is expected to return home about 45
  minutes after the procedure is completed. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>About
  Conceptus </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Conceptus, Inc. is developing Essure, an innovative medical procedure, designed to provide a non-incisional alternative to
  tubal ligation, the leading form of birth control worldwide. The availability of Essure in the U.S. is expected to open up a market currently occupied by surgical tubal ligation and vasectomy, which combined account for over 1 million procedures in
  the United States. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">The Essure procedure is based on a unique and proprietary implant and catheter delivery system for minimally invasive
  transcervical tubal access. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><I>Except for the historical information contained herein, the matters discussed in this press release are
  forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The receipt of regulatory approvals, results of product development programs, and clinical efficacy of and market demand for our product, among
  other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be based upon factors within the Company&#146;s control, such as strategic planning
  decisions by management and re-allocation of internal resources, or on factors outside of the Company&#146;s control, such as delays by regulatory authorities, scientific advances by third parties and introduction of competitive products, as well as
  those factors set forth in the Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2001 and other filings with the Securities and Exchange Commission. </I></FONT></DIV> <P></P>
   <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">3 </FONT></DIV>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#CCEEFF" WIDTH="100%" ALIGN="CENTER">
  
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>SIGNATURES </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV
  STYLE="text-indent:4%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
  authorized. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="right">
  <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">
  
  <TR>
  <TD VALIGN="top" COLSPAN="3" WIDTH="43%"> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">CONCEPTUS, INC.</FONT></DIV> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman"
  SIZE="2" COLOR="#000000">(Registrant)</FONT></DIV> </TD> </TR>
  <TR>
  <TD HEIGHT="16"> </TD> </TR>
  <TR>
  <TD VALIGN="top" WIDTH="3%"> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">By:</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" WIDTH="43%"> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">&nbsp;&nbsp;&nbsp;&nbsp;/s/&nbsp;&nbsp;&nbsp;&nbsp;G<SMALL>LEN</SMALL> K. F<SMALL>URUTA</SMALL></FONT></DIV> <HR NOSHADE
  COLOR="#000000" ALIGN="left"></TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="43%"> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Glen K. Furuta</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Vice President, Finance &amp;
  Administration</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">and Chief Financial Officer</FONT></DIV> </TD> </TR>
   </TABLE> </DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Dated:&nbsp;&nbsp;&nbsp;&nbsp;July 23, 2002
  </FONT></DIV> <P></P>
   <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">4 </FONT></DIV>
  
   </BODY></HTML>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "d8k.htm", "description": "FORM 8-K DATED JULY 22, 2002", "secsgml_size_bytes": 13507}]
metadata_filer: {"company-data": {"conformed-name": "CONCEPTUS INC", "cik": "0000896778", "assigned-sic": "3841", "irs-number": "973170244", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27596", "film-number": "02708514"}, "business-address": {"street1": "1021 HOWARD AVE", "city": "SAN CARLOS", "state": "CA", "zip": "94070", "phone": "4158027240"}, "mail-address": {"street1": "1021 HOWARD AVENUE", "city": "SAN CARLOS", "state": "CA", "zip": "94070"}}
text: Prepared by R.R. Donnelley Financial -- Form 8-K Dated July 22, 2002
  SECURITIES AND EXCHANGE COMMISSION
  WASHINGTON, D.C. 20549
  FORM 8-K
  CURRENT REPORT
  PURSUANT TO SECTION 13 OR 15(d) OF THE
  SECURITIES EXCHANGE
  ACT OF 1934
  Date of Report (Date of earliest event reported): July 22,
  2002
  CONCEPTUS, INC.
  (Exact name of registrant as specified in charter)
  Delaware
  (State or other
  jurisdiction of
  incorporation or organization)
  000-27596
  (Commission file
  number)
  94-3170244
  (I.R.S.
  employer
  identification no.)
  1021 Howard Avenue
  San Carlos, CA 94070
  (Address of principal executive offices) (Zip code)
  Registrant's telephone number, including area code: (650) 802-7240
  ITEM 5.    OTHER EVENTS.
  On July 22, 2002, Conceptus, Inc. issued a press release announcing that the Obstetrics and Gynecological Devices Advisory Committee of the United States Food
  and Drug Administration (FDA) recommended approval for Essure
  ™
  . Text of the press release follows:
  Rockville, MD, July 22, 2002 – Conceptus, Inc. (NASDAQ NM: CPTS) today announced that the Obstetrics and Gynecological Devices
  Advisory Committee of the United States Food and Drug Administration (FDA) recommended approval for Essure
  ™
  , the first alternative to tubal ligation for women seeking permanent contraception. The committee, by a vote of 8-0 with one abstention, recommended that Essure be approved once certain conditions are met. These
  conditions include changes to the labeling and implementation of the company's pre-existing plan to conduct post-marketing surveillance. Although Advisory Committee recommendations are not binding on the FDA, typically FDA final determinations
  are consistent with their recommendations. In May, the Essure PMA (Pre-Market Approval Application) was granted expedited review status by the FDA. The Essure device is investigational in the United States and currently marketed in Australia,
  Europe, Singapore and Canada.
  Currently, an estimated 700,000 American women undergo tubal ligation each year, making it the most common
  form of contraception in the United States. Unlike tubal ligation, which requires cutting into the abdominal cavity, and is typically done under general anesthesia with a four to six day recovery period, Essure requires no incisions, can be
  performed without general anesthesia and most patients are able to return to their regular physical activities within one day.
  "After researchers have worked for more than three decades to develop an alternative to surgical tubal ligation, Conceptus is extremely proud to have developed Essure and be one step closer to bringing this breakthrough option
  to women seeking permanent birth control," said Steve Bacich, President and CEO of Conceptus. "We are pleased that the Advisory Committee has recommended Essure for approval. When all FDA questions are answered, and if approval is given,
  we will work to make the procedure available as quickly as possible to women in the United States."
  2
  "Alternatives to incisional permanent birth control procedures represent an unmet need in this
  country," said Jay M. Cooper, M.D., founder and medical director of Women's Health Research Center, Phoenix, Arizona, and the principal U.S. investigator of Essure. "By offering women a procedure without an incision, without general
  anesthesia and without significant disruption to their family or work life, Essure could ultimately change the face of permanent contraception."
  About Essure
  Essure deploys a
  soft micro-insert into the fallopian tube through the cervix using a minimally invasive transcervical tubal access catheter. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or
  blockage in the fallopian tube. An Essure procedure does not require cutting or penetrating the abdomen and can be performed in a less costly procedure setting without general anesthesia. Accordingly, a woman is expected to return home about 45
  minutes after the procedure is completed.
  About
  Conceptus
  Conceptus, Inc. is developing Essure, an innovative medical procedure, designed to provide a non-incisional alternative to
  tubal ligation, the leading form of birth control worldwide. The availability of Essure in the U.S. is expected to open up a market currently occupied by surgical tubal ligation and vasectomy, which combined account for over 1 million procedures in
  the United States.
  The Essure procedure is based on a unique and proprietary implant and catheter delivery system for minimally invasive
  transcervical tubal access.
  Except for the historical information contained herein, the matters discussed in this press release are
  forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The receipt of regulatory approvals, results of product development programs, and clinical efficacy of and market demand for our product, among
  other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be based upon factors within the Company's control, such as strategic planning
  decisions by management and re-allocation of internal resources, or on factors outside of the Company's control, such as delays by regulatory authorities, scientific advances by third parties and introduction of competitive products, as well as
  those factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2001 and other filings with the Securities and Exchange Commission.
  3
  SIGNATURES
  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
  authorized.
  CONCEPTUS, INC.
  (Registrant)
  By:
  /s/    G
  LEN
  K. F
  URUTA
  Glen K. Furuta
  Vice President, Finance &
  Administration
  and Chief Financial Officer
  Dated:    July 23, 2002
  4